Related Experiment Video
Updated: Jul 6, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Therapeutic interventions for autosomal dominant polycystic kidney disease
1Division of Renal Diseases, University of Colorado Health Sciences Center, Denver, USA.
Insights
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder leading to kidney failure. Current research focuses on clinical trials for new treatments like Tolvaptan, Octreotide, and ACE inhibitors to manage ADPKD.
Area of Science:
- Nephrology
- Genetics
- Pharmacology
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent life-threatening hereditary condition in the U.S.
- ADPKD leads to end-stage renal disease, necessitating dialysis or transplantation.
- Currently, no definitive treatment exists for human ADPKD.
Purpose of the Study:
- To review current therapeutic interventions for ADPKD.
- To highlight ongoing clinical trials for ADPKD management.
- To identify key drugs being investigated for ADPKD treatment.
Main Methods:
- Review of existing literature on ADPKD treatments.
- Analysis of ongoing clinical trials for ADPKD.
- Identification of therapeutic agents under investigation.
Main Results:
- Multiple clinical trials are actively testing various interventions for ADPKD in both pediatric and adult populations.
- Key therapeutic agents under investigation include Tolvaptan, Octreotide, Sirolimus, Everolimus, statins, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs).
Conclusions:
- The landscape of ADPKD treatment is evolving with numerous clinical trials underway.
- A range of pharmacological interventions show promise for managing ADPKD progression and complications.
- Further research and clinical data are crucial to establish effective ADPKD therapies.
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening hereditary disease in the United States and causes end-stage renal failure requiring dialysis and renal transplantation. There is no effective treatment for ADPKD in humans. However, there are now multiple clinical trials testing a host of therapeutic interventions in children and adults with ADPKD. The major therapeutic interventions being tested in patients with ADPKD include Tolvaptan, Octreotide, Sirolimus, Everolimus, and statins, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome III : Nursing Management

